Septerna Financial Ratios
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
38.37+1.47 (+3.98%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Septerna ratio analysis
Septerna earned a net margin of -106.4% in FY 2025, up from -6678.9% a year earlier. Return on equity reached -12.8%, meaning Septerna generated -0.13 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Septerna financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 26.95 | 217.97 | — |
| Price / book | 3.24 | 0.56 | — |
| Operating margin | -148.6% | -7,518.4% | 1,374.2% |
| Net margin | -106.4% | -6,678.9% | 2,768.2% |
| Free cash flow margin | 238.7% | -6,471.9% | -27,550.3% |
| Return on equity (ROE) | -12.8% | -17.1% | — |
| Return on assets (ROA) | -8.2% | -15.7% | 3.2% |
| Current ratio | 4.73 | 27.77 | 16.30 |
| Revenue growth | 4,174.5% | 611.9% | — |
| EPS growth | — | -2,603.4% | — |